Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chemotherapy Induced Neutropenia-Pipeline Review, H1 2015

Chemotherapy Induced Neutropenia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chemotherapy Induced Neutropenia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Neutropenia-Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chemotherapy Induced Neutropenia Overview 10

Therapeutics Development 11

Pipeline Products for Chemotherapy Induced Neutropenia-Overview 11

Pipeline Products for Chemotherapy Induced Neutropenia-Comparative Analysis 12

Chemotherapy Induced Neutropenia-Therapeutics under Development by Companies 13

Chemotherapy Induced Neutropenia-Therapeutics under Investigation by Universities/Institutes 16

Chemotherapy Induced Neutropenia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Chemotherapy Induced Neutropenia-Products under Development by Companies 21

Chemotherapy Induced Neutropenia-Products under Investigation by Universities/Institutes 24

Chemotherapy Induced Neutropenia-Companies Involved in Therapeutics Development 25

Bio-Ker s.r.l 25

Biogenomics Limited 26

Bolder Biotechnology, Inc. 27

Cellerant Therapeutics, Inc. 28

Coherus BioSciences, Inc. 29

Dong-A Socio Group 30

Generon (Shanghai) Corporation Ltd. 31

Hanmi Pharmaceuticals, Co. Ltd. 32

Io Therapeutics, Inc. 33

Mycenax Biotech Inc. 34

Myelo Therapeutics GmbH 35

Octapharma AG 36

PharmaEssentia Corporation 37

Reliance Life Sciences Pvt. Ltd. 38

Richter Gedeon Nyrt. 39

Sandoz Inc. 40

Sandoz International GmbH 41

Teva Pharmaceutical Industries Limited 42

UAB Profarma 43

USV Limited 44

Welichem Biotech Inc. 45

XBiotech USA, Inc. 46

Chemotherapy Induced Neutropenia-Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

balugrastim-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

BBT-007-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BBT-015-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BBT-018-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

BK-0026-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Cell Therapy for Chemotherapy Induced Neutropenia-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

F-627-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

filgrastim-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

filgrastim-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

filgrastim-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

filgrastim-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

filgrastim-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

filgrastim-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

filgrastim-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

filgrastim (recombinant)-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

GW-003-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

HM-10460A-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

IRX-4310-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

lipegfilgrastim-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Myelo-001-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

pegfilgrastim-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

pegfilgrastim-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

pegfilgrastim-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

pegfilgrastim-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

pegfilgrastim-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

pegfilgrastim-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

pegfilgrastim-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

pegfilgrastim-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Recombinant Protein for Chemotherapy Induced Neutropenia-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

romyelocel-L-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

TXA-302-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

WBI-2100-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Chemotherapy Induced Neutropenia-Recent Pipeline Updates 92

Chemotherapy Induced Neutropenia-Dormant Projects 98

Chemotherapy Induced Neutropenia-Discontinued Products 100

Chemotherapy Induced Neutropenia-Product Development Milestones 101

Featured News & Press Releases 101

Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 101

Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 102

May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012-A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 103

Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 103

Nov 18, 2013: Teva announces Launch of LONQUEX Injection 104

Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 105

Jun 03, 2013: Teva's Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 105

Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 106

Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 106

Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 107

Appendix 108

Methodology 108

Coverage 108

Secondary Research 108

Primary Research 108

Expert Panel Validation 108

Contact Us 109

Disclaimer 109

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2015 11

Number of Products under Development for Chemotherapy Induced Neutropenia-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Comparative Analysis by Unknown Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Chemotherapy Induced Neutropenia-Pipeline by Bio-Ker s.r.l, H1 2015 25

Chemotherapy Induced Neutropenia-Pipeline by Biogenomics Limited, H1 2015 26

Chemotherapy Induced Neutropenia-Pipeline by Bolder Biotechnology, Inc., H1 2015 27

Chemotherapy Induced Neutropenia-Pipeline by Cellerant Therapeutics, Inc., H1 2015 28

Chemotherapy Induced Neutropenia-Pipeline by Coherus BioSciences, Inc., H1 2015 29

Chemotherapy Induced Neutropenia-Pipeline by Dong-A Socio Group, H1 2015 30

Chemotherapy Induced Neutropenia-Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 31

Chemotherapy Induced Neutropenia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 32

Chemotherapy Induced Neutropenia-Pipeline by Io Therapeutics, Inc., H1 2015 33

Chemotherapy Induced Neutropenia-Pipeline by Mycenax Biotech Inc., H1 2015 34

Chemotherapy Induced Neutropenia-Pipeline by Myelo Therapeutics GmbH, H1 2015 35

Chemotherapy Induced Neutropenia-Pipeline by Octapharma AG, H1 2015 36

Chemotherapy Induced Neutropenia-Pipeline by PharmaEssentia Corporation, H1 2015 37

Chemotherapy Induced Neutropenia-Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 38

Chemotherapy Induced Neutropenia-Pipeline by Richter Gedeon Nyrt., H1 2015 39

Chemotherapy Induced Neutropenia-Pipeline by Sandoz Inc., H1 2015 40

Chemotherapy Induced Neutropenia-Pipeline by Sandoz International GmbH, H1 2015 41

Chemotherapy Induced Neutropenia-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 42

Chemotherapy Induced Neutropenia-Pipeline by UAB Profarma, H1 2015 43

Chemotherapy Induced Neutropenia-Pipeline by USV Limited, H1 2015 44

Chemotherapy Induced Neutropenia-Pipeline by Welichem Biotech Inc., H1 2015 45

Chemotherapy Induced Neutropenia-Pipeline by XBiotech USA, Inc., H1 2015 46

Assessment by Monotherapy Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Chemotherapy Induced Neutropenia Therapeutics-Recent Pipeline Updates, H1 2015 92

Chemotherapy Induced Neutropenia-Dormant Projects, H1 2015 98

Chemotherapy Induced Neutropenia-Dormant Projects (Contd..1), H1 2015 99

Chemotherapy Induced Neutropenia-Discontinued Products, H1 2015 100

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2015 11

Number of Products under Development for Chemotherapy Induced Neutropenia-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 47

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 48

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 51

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bio-Ker s.r.l

Biogenomics Limited

Bolder Biotechnology, Inc.

Cellerant Therapeutics, Inc.

Coherus BioSciences, Inc.

Dong-A Socio Group

Generon (Shanghai) Corporation Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Io Therapeutics, Inc.

Mycenax Biotech Inc.

Myelo Therapeutics GmbH

Octapharma AG

PharmaEssentia Corporation

Reliance Life Sciences Pvt. Ltd.

Richter Gedeon Nyrt.

Sandoz Inc.

Sandoz International GmbH

Teva Pharmaceutical Industries Limited

UAB Profarma

USV Limited

Welichem Biotech Inc.

XBiotech USA, Inc.

Chemotherapy Induced Neutropenia Therapeutic Products under Development, Key Players in Chemotherapy Induced Neutropenia Therapeutics, Chemotherapy Induced Neutropenia Pipeline Overview, Chemotherapy Induced Neutropenia Pipeline, Chemotherapy Induced Neutropenia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com